Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Eligibility criteria for NHS-funded GLP-1 treatment for weight management include: For semaglutide (Wegovy): BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity For liraglutide (Saxenda): Similar BMI criteria as defined in NICE TA664 Evidence of previous weight management attempts through lifestyle modification Treatment must be initiated within specialist weight management services (Tier 3) Time-limited use as specified in the relevant NICE guidance The referral pathway typically involves: Initial GP consultation: Discuss weight concerns, document BMI and comorbidities, and review previous weight management efforts Tier 2/3 weight management services: Many areas require participation in structured lifestyle programmes before pharmacological intervention Specialist assessment: Referral to specialist weight management services for treatment initiation Ongoing monitoring: Regular review to assess response, tolerability, and continuation criteria Treatment continuation requires achieving the weight loss thresholds specified in the product-specific NICE guidance and SmPCs
That is not a comprehensive model of care
72% male) from 804 sites in 41 countries with overweight or obesity (BMI of 27 kg/m or higher) were enrolled and treated with semaglutide (2.4mg) or placebo for an average of 40 months
Clinical studies with liraglutide, for example, demonstrated enhanced hepatic insulin sensitivity, with suppression of endogenous glucose production by 9.36% under low-dose insulin infusion compared with 2.54% in placebo-treated controls
FAQ Do I need to take supplements while on GLP-1 medications
Serotonin production Vitamin C is also essential for the synthesis of serotonin, during which it hydroxylates the amine tryptophan to 5-hydroxy tryptophan
